{"product_id":"ucb-marketing-mix","title":"UCB Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how UCB’s product development, pricing architecture, distribution channels, and promotion tactics combine to drive market performance. This concise 4P snapshot highlights strengths, gaps, and competitive levers. Want the full, editable Marketing Mix Analysis with data, examples, and ready-to-use slides? Purchase the complete report to save hours and apply proven insights immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted therapies for immunology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiologic medicines from UCB target severe immunological conditions such as psoriasis, psoriatic arthritis, hidradenitis suppurativa and axial spondyloarthritis, addressing a global immunology biologics market valued at ~USD 85bn in 2023 with ~6% CAGR to 2028. Differentiation is through targeted mechanisms, robust efficacy and growing long‑term safety datasets from pivotal and real‑world studies. User‑centric formulations and autoinjector devices improve adherence by up to ~25% versus traditional delivery, while lifecycle plans—new indications, flexible dosing and patient‑friendly packaging—can expand the addressable population by ~15%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurology portfolio for chronic brain diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUCBs neurology portfolio targets epilepsy, myasthenia gravis, Parkinson’s-related complications and other chronic brain disorders, addressing seizure control and functional outcomes for conditions that affect roughly 50 million people with epilepsy and over 10 million with Parkinson’s globally. Evidence highlights quality-of-life gains from improved seizure reduction and functional measures. Extended-release and precision formulations enhance stability and convenience, while integration with digital monitoring tools supports adherence and disease management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient support and services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUCB patient support and services combine nurse support, onboarding, injection-device training, reimbursement navigation and adherence coaching to lower initiation barriers and enhance therapy continuity.\u003c\/p\u003e\n\u003cp\u003eDigital apps, reminders and education have been shown to increase persistence by ~25% and reduce drop-off; reimbursement navigation can cut abandonment by up to ~30%.\u003c\/p\u003e\n\u003cp\u003eMultilingual resources cover key markets to address diverse needs and improve engagement across patient segments.\u003c\/p\u003e\n\u003cp\u003eReal-time feedback loops from 2024 program data drive product improvements and optimized care pathways, informing clinical and commercial decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion diagnostics and biomarkers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompanion diagnostics partnerships enable precise patient identification, stratification and longitudinal monitoring, with biomarker-driven programs showing up to 2x higher response rates and ~30% shorter time-to-therapy in recent oncology programs (2024–25). Co-development with centralized labs streamlines standardization, reimbursement access and rollout. Diagnostic-derived RWE feeds outcomes research and health-economics modeling to de-risk launches.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient ID\/stratification: ↑eligibility capture\u003c\/li\u003e\n\u003cli\u003eClinical impact: ≈2x response, ~30% faster therapy\u003c\/li\u003e\n\u003cli\u003eOperational: lab co-dev → standardized assays, faster market access\u003c\/li\u003e\n\u003cli\u003eData: diagnostic RWE → CER, HEOR, payer evidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline and innovation platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUCBs pipeline (2025) features 5+ late-stage assets extending into adjacent immunology and neurology indications, with modalities across biologics, small molecules and novel mechanisms; R\u0026amp;D emphasizes patient-centric endpoints and translational biomarkers to de-risk trials and speed registrational pathways.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 pipeline: 5+ late-stage programs\u003c\/li\u003e\n\u003cli\u003eModalities: biologics, small molecules, novel mechanisms\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D focus: patient-centric endpoints, translational science\u003c\/li\u003e\n\u003cli\u003eStrategy: in-house discovery plus external licensing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision biologics and companion diagnostics double responses and boost adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUCB products address severe immunology and neurology needs with biologics\/small molecules, targeting a 2023 immunology biologics market ~USD 85bn (≈6% CAGR to 2028). Differentiation: targeted mechanisms, long‑term safety and patient‑centric delivery improving adherence ~25%. Companion diagnostics double response rates and speed therapy ~30%; 2025 pipeline: 5+ late‑stage assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunology market (2023)\u003c\/td\u003e\n\u003ctd\u003e~USD 85bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAGR to 2028\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence (autoinjector)\u003c\/td\u003e\n\u003ctd\u003e+25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital persistence\u003c\/td\u003e\n\u003ctd\u003e+25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement abandonment\u003c\/td\u003e\n\u003ctd\u003e-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomarker response lift\u003c\/td\u003e\n\u003ctd\u003e≈2x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline (2025)\u003c\/td\u003e\n\u003ctd\u003e5+ late‑stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a company-specific deep dive into UCB's Product, Price, Place, and Promotion strategies, combining real brand practices and competitive context; ideal for managers, consultants, and marketers needing a structured, ready-to-use strategic brief.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTurn the UCB 4P's Marketing Mix Analysis into a concise, plug-and-play summary that distills complex strategy into an at-a-glance format for leadership and cross-functional teams. Perfect for meetings, decks, or workshops, it speeds alignment, simplifies decision-making, and lets non-marketing stakeholders quickly grasp UCB’s commercial direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty distribution to hospitals and clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProducts are channeled through specialty wholesalers to infusion centers, hospitals, and specialist practices. Access management ensures supply continuity for chronic therapies with industry-standard 95% on-time fill targets and hub programs. Account teams coordinate formulary placement and pathway inclusion via payer dossiers and tenders. Cold-chain integrity is maintained end-to-end at 2-8°C with continuous temperature logs and real-time monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy networks and home delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty and retail pharmacies dispense self-injectable and oral therapies, with specialty drugs accounting for ~51% of U.S. drug spend (IQVIA 2024); hub services coordinate prior authorizations and copay assistance for the majority of specialty starts, speeding initiation. Home delivery boosts convenience for stable patients and can raise adherence by up to 20% in chronic therapies, while pharmacist counseling supports adherence and safety monitoring through medication reconciliation and adverse-event triage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access across major regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated teams manage pricing, reimbursement and tenders in the US, EU5, Japan and other key markets; local affiliates in over 40 countries adapt to country-specific HTA requirements across EU5 (UK, DE, FR, IT, ES). Distribution partners extend reach to products available in more than 100 countries, while supply planning is synchronized regionally to match demand and regulatory release timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital channels and remote onboarding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSecure portals facilitate patient enrollment, training, and follow-up, enabling tracked adherence and secure data exchange for decentralized trials and therapy support.\u003c\/p\u003e\n\u003cp\u003eTelehealth-enabled education reduces friction in initiation by delivering remote nurse-led onboarding and real-time troubleshooting at point of care.\u003c\/p\u003e\n\u003cp\u003eE-sampling and e-consent streamline HCP engagement where compliant, shortening sample-to-prescription cycles and improving documentation traceability.\u003c\/p\u003e\n\u003cp\u003eAnalytics guide inventory allocation and service capacity by predicting demand patterns and optimizing cold-chain and nurse-resource deployment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient portals: enrollment, training, follow-up\u003c\/li\u003e\n\u003cli\u003eTelehealth: remote education, initiation friction reduction\u003c\/li\u003e\n\u003cli\u003eE-sampling\/e-consent: compliant HCP engagement\u003c\/li\u003e\n\u003cli\u003eAnalytics: inventory allocation, service capacity planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and investigator networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinical sites and centers of excellence support UCB trials, early access and post-marketing studies, accelerating evidence generation and physician familiarity to smooth uptake. Expanded access programs bridge pre-approval gaps—FDA approves over 99% of expanded access requests—while site insights refine launch sequencing and medical education priorities.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNetworks: drive rapid evidence generation\u003c\/li\u003e\n\u003cli\u003eExpanded access: FDA \u0026gt;99% approvals\u003c\/li\u003e\n\u003cli\u003eInsights: inform launch sequencing and HCP education\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty therapies: \u003cstrong\u003e2–8°C\u003c\/strong\u003e cold chain, \u003cstrong\u003e95%\u003c\/strong\u003e on-time fills\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUCB places specialty therapies via wholesalers, specialty\/retail pharmacies and home delivery, maintaining 2–8°C cold chain and 95% on-time fill targets for chronic therapies. Hub services drive prior auth, copay support and ~20% higher adherence with home delivery; specialty drugs represent ~51% of US drug spend (IQVIA 2024). Global reach covers 100+ countries with local teams handling HTA\/tenders and expanded access (FDA \u0026gt;99% approvals).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain\u003c\/td\u003e\n\u003ctd\u003e2–8°C, real-time monitoring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time fill\u003c\/td\u003e\n\u003ctd\u003e~95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS specialty spend\u003c\/td\u003e\n\u003ctd\u003e~51% (IQVIA 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome delivery impact\u003c\/td\u003e\n\u003ctd\u003e+~20% adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal availability\u003c\/td\u003e\n\u003ctd\u003e100+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpanded access approvals\u003c\/td\u003e\n\u003ctd\u003eFDA \u0026gt;99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eUCB 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual UCB 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises. This is the exact, fully editable and comprehensive document included with your order. Buy with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675216593273,"sku":"ucb-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/ucb-marketing-mix.png?v=1755803826","url":"https:\/\/portersfiveforce.com\/products\/ucb-marketing-mix","provider":"Porter's Five Forces","version":"1.0","type":"link"}